Mitotech Europe initiated pre-clinical program for SkQ1 compound in the U.S.

Mitotech S.A. – a Luxembourg based subsidiary of Mitotech LLC – initiated its IND program in the U.S. Aim of the IND program is to repeat animal safety studies of its first drug Visomitin at independent U.S. laboratories and to seek IND approval for Visomitin with the FDA in late 2013.